Skip to nav Skip to content

News

Facebook Twitter LinkedIn Email

IDSA Response to Pfizer Request for COVID-19 Vaccine EUA

Barbara D. Alexander, M.D., MHS, FIDSA – President, Infectious Diseases Society of America on today’s Pfizer/BioNTech application for Emergency Use Authorization of its COVID-19 vaccine candidate

This Holiday Season Can Stand as a Turning Point in Our Nation’s Control of the COVID-19 Pandemic

With numbers of infections, illnesses, hospitalizations and deaths caused by COVID-19 at record highs as this holiday season begins, the risks posed by the spread of the coronavirus are more dangerous than at any time since its emergence last December.

Statement on the Emergency Use Authorization of Bamlanivimab

We share and appreciate the urgency in expanding therapeutic options for COVID-19 as daily case counts and hospitalization rates reach record levels. For new therapeutics to be used widely and routinely outside of clinical trials, we urge that there be sufficient safety and efficacy data to be confident regarding their use.

Senate Releases Appropriations With Continued Funding for the Ending the HIV Epidemic Initiative

The Senate Appropriations Committee’s funding proposal for FY2021 makes critical investments in the Ending the HIV Epidemic initiative and NIH but fails to include COVID-19 relief funding.

IDSA and HIVMA Congratulate the President-elect, Offer Guidance on Pandemic Response

The Infectious Diseases Society of America and its HIV Medicine Association have reached out today to President-elect Joe Biden to congratulate him and to offer their memberships’ expertise as the new administration takes on the challenges of the COVID-19 pandemic and other infectious diseases threats.

IDSA and HIVMA Release New Comprehensive Primary Care Guidance for People with HIV

New guidance published today by an expert panel of the HIV Medicine Association of the Infectious Diseases Society of America updates the 2013 guideline for providing comprehensive evidence-based primary care to people with HIV.

In Comments to DHS, Medical Societies Say Proposed Visa Rule for Physicians Will Exacerbate Our Disease Response Challenges

The Infectious Diseases Society of America, HIV Medicine Association, Pediatric Diseases Society and the Society of Healthcare Epidemiology of America have called on the Department of Homeland Security to exempt physicians working in the United States on J-1 visas from the agency’s proposed rule

Ignoring the Impacts of Inequities Stymies Science

"In September the Trump Administration released an “Executive Order on Combating Race and Sex Stereotyping,” which would allow federal agencies to terminate contracts intended to help promote study and understanding of diversity, equity and inclusion across government institutions."

Paper Describes Unique Opportunities for ID, HIV Professionals to Inform Improved Public Health Responses

A paper jointly published in Clinical Infectious Diseases and the Journal of Pediatric Infectious Diseases describes how the frontline experiences and perspectives of infectious diseases and HIV health care professionals have made pivotal differences to critical public health responses, from informing domestic and global efforts to prevent and contain pandemics

Order to Reclassify Civil Service Posts Will Compromise Responses to Public Health Threats

The executive order signed last week that strips protections from our nation’s civil service workforce comes at a time when the critical role of career staff in guiding federal responses to public health needs could not be more clear.

Routine HIV Screenings Decreased, Patients With Acute HIV Infections Increased In Chicago ERs During COVID

New research from a team of experts in Chicago shows a significant increase in the number of patients with acute HIV infections who sought treatment in their emergency department, possibly out of a fear of COVID-19, according to a study being presented at IDWeek 2020. Routine tests for HIV went down during this period.

Societies Urge FDA Advisory Committee to Maintain Standard, Existing and Transparent Process for COVID-19 Vaccine Review

The authorization or licensure of a COVID-19 vaccine must include the highest standards of thorough and transparent review to ensure the safety and effectiveness as well as the acceptance and uptake of an immunization against the novel coronavirus.

This website uses cookies

We use cookies to ensure that we give you the best experience on our website. Cookies facilitate the functioning of this site including a member login and personalized experience. Cookies are also used to generate analytics to improve this site as well as enable social media functionality.